CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 236 enrolled
Drug / intervention
Artemis + Medical Management +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03342664
NCT03342664N/ACompleted
CompareCT.gov

MIND: A Prospective, Multicenter Study of Artemis a Minimally Invasive Neuro Evacuation Device, in the Removal of Intracerebral Hemorrhage

Penumbra Inc.·interventional·Posted Nov 17, 2017·Updated Jan 30, 2026

In Brief

A clinical study evaluating Artemis + Medical Management and Best Medical Management Alone (MM) for Cerebral Hemorrhage and 3 related conditions. Completed, enrolled 236 participants across 33 sites in 4 countries.

Detailed Summary

The primary objective of this multicenter randomized controlled study is to compare the safety and efficacy of minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device to best medical management for the treatment of intracerebral hemorrhage (ICH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Hemorrhage, Brain Hemorrhage, Cerebral Parenchymal Hemorrhage, Intracerebral Hemorrhage
CountriesAustria, Canada, Germany, United States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedNov 17, 2017
Enrollment StartFeb 6, 2018
Primary CompletionFeb 20, 2024
Study CompletionSep 23, 2024
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 8.6 years ago

Interventions

Artemis + Medical Managementdevice

Subject will receive best MM in addition to the MIS procedure with Artemis.

Best Medical Management Alone (MM)other

Subject will receive best MM for ICH as determined by stroke physician following AHA/ESO guidelines.